Tirzepatide record · updated 18h ago
Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
What is Tirzepatide used for?
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has been investigated for its potential in managing type 2 diabetes and obesity. Its unique mechanism of action aims to enhance glycemic control and promote weight loss.
How it works: Dual GIP + GLP-1 receptor agonist
Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection
Development stage
where Tirzepatide sits between preclinical work and regulatory approval- 1ClearedPreclinicalAnimal / in-vitro work
- 2ClearedPhase 1Safety in humans
- 3ClearedPhase 2Efficacy signal
- 4ClearedPhase 3Confirmatory trials
- 5CurrentApprovedCleared by a regulator
Stage is inferred from the highest trial phase in the indexed corpus and 152 registered trials. It describes the research record, not a recommendation.
Identity
NameTirzepatide
Chain length—
Molecular weight4,813 Da
FormulaC225H348N48O68
Structure typeNot established
ClassMetabolic
Research levelFDA Approved
Discovered byAdded before provenance tracking · 2025
Mass and formula from PubChem CID 166567236. No verified residue count for this compound.
Pharmacology
MechanismDual GIP + GLP-1 receptor agonist
RouteSubcutaneous injection
Half-life~5 days (≈120 h)
Time to peak8–72 h
DurationWeekly dosing
Extraction confidence0.95
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 6, 2026. How this works →
Research stats
Total studies28
Human / animal / cellular14 / 2 / 1
Highest trial phasePhase 3
Years covered2010–2026
Latest study11d ago
Publication history
20102026
Research funding
48 NIH projects · $30.7M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports2,412
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records
What people are saying
anecdotal · not evidenceUnverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Tirzepatide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.
Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Tirzepatide is discussed should be drawn from it.
Articles mentioning Tirzepatide
- What Is Tirzepatide? What the Research Actually ShowsExplore what is tirzepatide, its dual receptor action, and what current research reveals about its efficacy in diabetes and obesity.definition · 8 min
- Do GLP 1 Patches Work? What the Evidence ShowsDo GLP 1 patches work? A skeptical look at OTC patches vs FDA-approved GLP-1 medications, and why transdermal delivery of large peptides is unproven.safety · 6 min
- Ozempic vs Wegovy vs Mounjaro: GLP-1 Drugs ComparedOzempic vs Wegovy vs Mounjaro explained: four brands, two molecules. Compare approved uses, mechanism, side effects, eligibility, and insurance coverage.comparison · 7 min
- GLP-1 Drugs List: Every Major Option ExplainedA complete GLP-1 drugs list: every major FDA-approved option with brand names, uses, and mechanism — plus investigational agents that are not approved.roundup · 5 min
- Liraglutide vs Semaglutide: How They CompareLiraglutide vs semaglutide compared: mechanism, brands, dosing frequency, formulations, side effects, and coverage. Both are FDA-approved and prescription-only.comparison · 7 min
- Mounjaro vs Ozempic Side Effects ComparedMounjaro vs Ozempic side effects compared: shared GI symptoms, boxed warnings, who is at higher risk, and how clinicians manage tolerability.comparison · 7 min
- Natural GLP 1: What Actually Raises ItNatural GLP 1 explained: how protein, fiber, and whole foods modestly raise your own GLP-1 — and why the effect is nothing like a prescription medication.how-to · 6 min
- Reddit Ozempic Threads: Common Themes, ExplainedWhat reddit ozempic threads discuss most — nausea, appetite change, plateaus, cost — plus the medical context and FDA label detail those threads often lack.roundup · 6 min
- Reddit Peptides: A Beginner's OrientationReddit peptides threads blend approved drugs, investigational agents, and research chemicals. A beginner's orientation, plus the medical context they lack.roundup · 6 min
- Retatrutide FDA Approval Status (2026 Update)Retatrutide FDA approval status: not approved as of July 2026. It's in Phase 3 trials, with an NDA expected and approval projected for 2027 at earliest.news · 5 min
- Retatrutide Reddit: Community Themes and Real ContextWhat retatrutide reddit threads commonly discuss — results, side effects, sourcing — plus the medical context those threads lack. Not FDA approved.roundup · 7 min
- Retatrutide Side Effects Reddit vs Trial DataWhat retatrutide side effects reddit threads report vs what clinical trials describe. Retatrutide is investigational and not FDA approved. Not medical advice.roundup · 7 min
- Retatrutide Side Effects: What Research ReportsRetatrutide side effects are mostly gastrointestinal and dose-related in trials. Retatrutide is investigational and not FDA-approved. Here's what's known.safety · 5 min
- Retatrutide vs Tirzepatide Reddit: The ContextRetatrutide vs tirzepatide Reddit threads miss one crucial fact: tirzepatide is FDA-approved, retatrutide is investigational. The medical context explained.roundup · 6 min
- Rybelsus vs Ozempic: Oral vs Injectable SemaglutideRybelsus vs Ozempic: same semaglutide, different form. Compare the daily oral tablet and the weekly injection on use, side effects, and coverage.comparison · 7 min
- Reddit Semaglutide Threads: Common Themes ExplainedReddit semaglutide threads: what people actually discuss — nausea, food noise, plateaus, compounded versions — plus the medical context those threads lack.roundup · 5 min
- Reddit Tirzepatide Threads: Common ThemesWhat Reddit tirzepatide threads discuss most — appetite, GI side effects, Mounjaro vs Zepbound, and access — plus the FDA status and medical context.roundup · 6 min
- Trulicity vs Ozempic: Comparing Two GLP-1 DrugsTrulicity vs Ozempic compared: dulaglutide and semaglutide are both once-weekly GLP-1 drugs for type 2 diabetes. Mechanism, side effects, and coverage.comparison · 7 min
- Reddit Wegovy Threads: Common Themes ExplainedWhat Reddit Wegovy threads commonly discuss about appetite, side effects, and access — plus the medical context and FDA status those posts leave out.roundup · 6 min
- Zepbound Reddit: Common Themes and the Real ContextWhat zepbound reddit threads discuss — appetite change, side effects, cost, plateaus — plus what the FDA label and evidence for tirzepatide actually say.roundup · 6 min
- Zepbound vs Mounjaro: Same Drug, Two BrandsZepbound vs Mounjaro: both are tirzepatide from Eli Lilly. The difference is the FDA-approved use — weight management vs type 2 diabetes.comparison · 6 min
- Zepbound vs Wegovy: How They Compare for Weight LossZepbound vs Wegovy: Zepbound is tirzepatide, Wegovy is semaglutide. Both are FDA-approved for weight management. Here's how the two compare.comparison · 6 min
- AOD-9604 vs Semaglutide: Why They're Not ComparableAOD-9604 and Semaglutide both appear in 'fat-loss peptide' conversations but they're not comparable interventions. Semaglutide is FDA-approved with ~15% trial weight loss; AOD-9604 has weak human evidence and minimal trial effect.comparison · 4 min
- BPC-157 vs Semaglutide: Healing Peptide vs Weight-Loss DrugBPC-157 and Semaglutide solve completely different problems — healing vs weight loss. Here's why the comparison comes up, what each actually does, and when (if ever) they're used together.comparison · 4 min
- Mounjaro vs Ozempic: Tirzepatide vs Semaglutide, Brand by BrandMounjaro is Tirzepatide; Ozempic is Semaglutide. Different molecules, different mechanisms, different effect sizes. Here's the brand-level comparison plus insurance and pen-format differences.comparison · 4 min
- Ozempic vs Wegovy: Same Drug, Different IndicationsOzempic and Wegovy are both Semaglutide. The differences are dose ceiling, FDA-approved indication, packaging, and insurance coverage — not the molecule. Here's how to think about them.comparison · 4 min
- Best Peptides for Fat Loss: Evidence-Based RoundupRanked roundup of peptides studied for fat loss — GLP-1 / GIP agonists, GH-axis fragments, and supporting metabolic peptides — with mechanism, evidence quality, and how to choose.weight-loss · 6 min
- Cagrilintide Explained: Amylin Agonist + CagriSema CombinationCagrilintide (AM833) is Novo Nordisk's long-acting amylin receptor agonist. Combined with Semaglutide it produces ~17–22% weight loss in Phase 3 trials with a different mechanism than GLP-1.news · 4 min
- Retatrutide Explained: The Triple-Receptor Weight-Loss Drug in Phase 3Retatrutide (LY3437943) is a GLP-1 + GIP + glucagon triple receptor agonist producing ~24% weight loss at 48 weeks in Phase 2 trials. Here's what it is, how it works, and where it stands.news · 4 min
- Semaglutide vs Tirzepatide: Mechanism, Trial Data, Which to ChooseSemaglutide vs Tirzepatide — head-to-head on mechanism (GLP-1 vs GIP+GLP-1), Phase 3 weight loss (~15% vs ~21%), side effects, cardiovascular evidence, and how to choose.comparison · 6 min
- Tirzepatide vs Retatrutide: Dual vs Triple Receptor AgonismTirzepatide is FDA-approved GIP+GLP-1 dual agonism (~21% weight loss). Retatrutide is GLP-1+GIP+glucagon triple agonism in Phase 3 (~24% Phase 2). Here's how they compare.comparison · 5 min
- Peptide Stack for Weight Loss: Defensible CombinationsWhat 'peptide stack for weight loss' actually means — the defensible combinations (CagriSema, GLP-1 + Tesamorelin, GLP-1 + healing peptides), what to avoid, and why training plus protein is the load-bearing partner.stack · 5 min